

Supplementary Table 1: Demographic, clinical and biological patient data

Number of patients (n)	
Female/male	34/6
Incident/relapse	31/9
Age (years, median, IQR)	25 (22-35)
Ethnicity (n)	
Caucasian	30
African	6
Asian	3
Other	1
Duration between SLE and nephritis diagnosis (years, median, IQR)	2.8 (0.07-6.2)
Serum dsDNA antibody titers (u/mL, median, IQR)	192 (107-606.4)
Serum C3 (mg/dL, median, IQR)	0.6 (0.4-0.8)
eGFR (mL/min/1.73m², median, IQR)	
Baseline (n=40)	89 (66-111)
1-year follow-up (n=40)	93 (74-105)
5-year follow-up (n=37)	95 (72-109)
Proteinuria (urinary protein/creatinine ratio, g/g, median, IQR)	2.1 (1.4-4.4)
ISN/RPS classification (number of biopsies)	
Class III (+V)	7
Class IV (+V)	33
Sclerosis score (median, IQR)	1 (0-2)
NIH chronicity index (median, IQR)	2 (0.5-3)
NIH activity index (median, IQR)	7 (4.5-9)
Treatment initiated after biopsy	
Induction therapy	
IV cyclophosphamide (n, 0.5-1g/monthly/8 pulses)	2
Euro-Lupus: IV cyclophosphamide (n, 500mg/biweekly/6 pulses)	26
Mycophenolate mofetil (n, 2-3g/day)	12
Maintenance therapy	
Mycophenolate mofetil (n, 1-2g/day)	20
Azathioprine (n, 2mg/kg/day)	20